Hot Stock
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige
AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion
2,67 EUR
±0,00 %±0,00
23. Nov, 12:59:39 Uhr,
Lang & Schwarz
Kommentare 1.141
H
Hopper58,
12.07.2024 17:18 Uhr
1
????? AbCellera price target lowered to $5 from $7 at KeyBanc
TheFly
Jul 11, 2024, 12:20 PM
KeyBanc lowered the firm’s price target on AbCellera to $5 from $7 and keeps an Overweight rating on the shares. The firm’s credit card data continues to show healthy utilization levels across hospital systems post the Change Healthcare outage, with hospital customer levels up high single digits in May and June year over year, but the ongoing robust employment data for healthcare systems keeps the firm wary of potential spending for hospital-exposed names, the analyst tells investors in a research note.' https://www.tipranks.com/news/the-fly/abcellera-price-target-lowered-to-5-from-7-at-keybanc?mod=mw_quote_news#google_vignette
H
Hopper58,
10.07.2024 6:56 Uhr
0
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
Zacks Equity Research July 09, 2024
'For the fiscal year ending December 2024, this company is expected to earn -$0.60 per share, which is a change of -17.7% from the year-ago reported number.
Analysts have been steadily raising their estimates for AbCellera Biologics. Over the past three months, the Zacks Consensus Estimate for the company has increased 7.4%.' https://www.zacks.com/stock/news/2298670/abcellera-biologics-abcl-upgraded-to-buy-heres-what-you-should-know?cid=CS-MKTWTCH-HL-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2298670&mod=mw_quote_news
H
Hopper58,
08.07.2024 17:08 Uhr
0
AI Could Revolutionize Drug Discovery: A Look at Key Players
Paul Hoffman
Jul 08, 2024, 04:53 PM
Story Highlights
The future of AI-driven drug discovery looks promising as companies continue to progress in their clinical trials and partnerships.
Artificial intelligence (AI) could have the potential to revolutionize drug discovery and bring new treatments to market, saving time and billions of dollars in research. This is because, currently, before any new drug gets full approval, it typically takes over a decade and, on average, over $1 billion to get to that point. However, the capabilities of AI in drug discovery have the potential to dramatically reduce this hurdle with the hope of making the process more efficient and effective.
The companies that have taken the lead in dramatically altering the current structure by adopting AI-based drug discovery could be tomorrow’s overlooked big winners. Below, we’ll explore four leaders in this realm as we look at the specialization of Recursion Pharmaceuticals (NASDAQ:RXRX), AbCellera Biologics (NASDAQ:ABCL), Relay Therapeutics (NASDAQ:RLAY), and Schrodinger (NASDAQ:SDGR). All are being closely watched by analysts, as their clinical data readouts could significantly impact their stock valuations.
AbCellera: Leveraging AI
AbCellera leverages a vast database of immune cells and antibodies to identify drug candidates. The company has prioritized collaborative relationships with partners like Prelude Therapeutics (NASDAQ:PRLD), Incyte (NASDAQ:INCY), and Biogen (NASDAQ:BIIB). AbCellera’s internal research is in the early stages, with a program in metabolic and endocrine disease potentially leading to a first-in-class treatment. Piper Sandler (NYSE:PIPR) analyst Allison Bratzel remains optimistic, stating, “We like the long-term setup on this name.”
H
Hopper58,
08.07.2024 15:23 Uhr
0
????: Regeneron Expects Earnings Hit After $24 Million R&D Charge
Published: July 8, 2024 at 7:45 a.m. ET
By Don Nico Forbes
Regeneron Pharmaceuticals expects to incur an acquired in-process research and development charge of about $24 million in the second quarter, which should negatively impact earnings per share.
The biotechnology company said the charge will likely hit net income per diluted share for the quarter by roughly 18 cents.
Regeneron said the charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
Arras,
08.07.2024 0:10 Uhr
0
Ich bin mir ziemlich sicher sollte es bei abfickerer weiter so gehen wie bislang sind wir nächstes Jahr unter einem Euro
H
Hopper58,
06.07.2024 12:14 Uhr
0
Ich denke, Abcellera spielte eine Rolle bei der Entdeckung dieser Medikamente. Siehe Vertrag zwischen beiden Unternehmen im Jahr 2022: Buy Rating on Regeneron: Promising Obesity Treatment Prospects Amid Phase 2 Trials Carrie Williams Jun 26, 2024, 09:37 AM David Risinger has given his Buy rating due to a combination of factors surrounding Regeneron’s innovative approach in the obesity treatment space. The recent Phase 1 study of trevogrumab and garetosmab, presented at a prestigious medical conference, indicated potential improvements in body composition and a slight decrease in body weight among participants. Although there were some safety concerns with muscle spasms reported, Regeneron has strategically designed a Phase 2 trial to mitigate side effects, particularly focusing on the use of garetosmab. The anticipation of significant Phase 2 outcomes, including the effects on body weight, fat, and muscle mass, set to be released in the second half of 2025, provides a promising outlook for the stock’s future performance. Furthermore, Risinger’s optimistic stance is reinforced by the observed increases in muscle mass and reductions in fat mass from the multiple dose data of the study. These positive trends, along with the meticulous study design that seeks to enhance efficacy while minimizing adverse effects, contribute to the favorable evaluation of Regeneron’s shares. The company’s cautious approach in not including any obesity revenues in its financial model due to the early stage of the program suggests a conservative and potentially upside-biased financial projection. This prudence, paired with the potential for a breakthrough in a challenging therapeutic area like obesity, underscores the rationale behind the Buy rating for Regeneron. According to TipRanks, Risinger is a 5-star analyst with an average return of 12.5% and a 59.24% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Sanofi. https://www.tipranks.com/news/blurbs/buy-rating-on-regeneron-promising-obesity-treatment-prospects-amid-phase-2-trials?mod=mw_quote_news
Ich habe alles untersucht, finde aber keine Beweise, dass Abcellera an diesen beiden genannten Antikörpern beteiligt war. Es handelte sich jedoch um denselben Anwendungsbereich. Entschuldigen Sie.
Arras,
04.07.2024 16:30 Uhr
0
Deshalb ist abcellera kein gesundes Unternehmen
Arras,
04.07.2024 16:30 Uhr
0
Naja abcellera hat in den letzten Jahren nur minus gemacht ihre Ausgaben sind viel höher als ihre Einnahmen
Hopper58,
03.07.2024 18:14 Uhr
0
Trotz sehr guter Nachrichten für Regeneron fiel der Preis um etwa 2 - 3 %. Aktionäre, die erkennen, dass das Obesitas-Medikament von Abcellera stammt und wechseln?
H
Hopper58,
03.07.2024 18:11 Uhr
0
Insolvenz: Totaler Unsinn. Abcellera hat mit Covid-Antikörpern rund 1 Milliarde US-Dollar verdient, es verbleiben 700 Millionen US-Dollar. Zum aktuellen Kurs liegen wir deutlich darunter.
H
Hopper58,
03.07.2024 8:38 Uhr
0
TD Cowen Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Jason Carr
Jun 28, 2024, 01:58 PM
In a report released today, Steven Mah from TD Cowen maintained a Buy rating on AbCellera Biologics (ABCL – Research Report). The company’s shares closed yesterday at $2.88.
According to TipRanks, Mah is an analyst with an average return of -17.5% and a 22.44% success rate. Mah covers the Healthcare sector, focusing on stocks such as Evotec AG, Twist Bioscience, and AbSci.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbCellera Biologics with a $12.60 average price target. https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-abcellera-biologics-abcl?mod=mw_quote_news
Hopper58,
03.07.2024 8:35 Uhr
0
Ich denke, Abcellera spielte eine Rolle bei der Entdeckung dieser Medikamente. Siehe Vertrag zwischen beiden Unternehmen im Jahr 2022:
Buy Rating on Regeneron: Promising Obesity Treatment Prospects Amid Phase 2 Trials
Carrie Williams
Jun 26, 2024, 09:37 AM
David Risinger has given his Buy rating due to a combination of factors surrounding Regeneron’s innovative approach in the obesity treatment space. The recent Phase 1 study of trevogrumab and garetosmab, presented at a prestigious medical conference, indicated potential improvements in body composition and a slight decrease in body weight among participants. Although there were some safety concerns with muscle spasms reported, Regeneron has strategically designed a Phase 2 trial to mitigate side effects, particularly focusing on the use of garetosmab. The anticipation of significant Phase 2 outcomes, including the effects on body weight, fat, and muscle mass, set to be released in the second half of 2025, provides a promising outlook for the stock’s future performance.
Furthermore, Risinger’s optimistic stance is reinforced by the observed increases in muscle mass and reductions in fat mass from the multiple dose data of the study. These positive trends, along with the meticulous study design that seeks to enhance efficacy while minimizing adverse effects, contribute to the favorable evaluation of Regeneron’s shares. The company’s cautious approach in not including any obesity revenues in its financial model due to the early stage of the program suggests a conservative and potentially upside-biased financial projection. This prudence, paired with the potential for a breakthrough in a challenging therapeutic area like obesity, underscores the rationale behind the Buy rating for Regeneron.
According to TipRanks, Risinger is a 5-star analyst with an average return of 12.5% and a 59.24% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Sanofi. https://www.tipranks.com/news/blurbs/buy-rating-on-regeneron-promising-obesity-treatment-prospects-amid-phase-2-trials?mod=mw_quote_news
Arras,
21.06.2024 9:05 Uhr
0
Unter 2 doller sind wir bald.
Arras,
18.06.2024 10:26 Uhr
0
Peter thiel ist net umsonst raus
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | AbCellera Biologics Hauptdiskussion | ||
| 2 | Daytrader ABCellera📈 |
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | MicroStrategy | +1,69 % | |
| 2 | NVIDIA Hauptdiskussion | +0,81 % | |
| 3 | Goldpreis Hauptdiskussion | ±0,00 % | |
| 4 | BTC/USD Hauptdiskussion | -1,02 % | |
| 5 | Ripple Hauptdiskussion | -0,16 % | |
| 6 | ROCK TECH LITHIUM Hauptdiskussion | ±0,00 % | |
| 7 | Nio für normale Kommunikation | ±0,00 % | |
| 8 | TESLA MOTORS Hauptdiskussion | +0,27 % | |
| 9 | CFC INDUSTRIE Hauptdiskussion | -3,70 % | |
| 10 | XRP zu USD Hauptdiskussion | +0,21 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | MicroStrategy | +1,69 % | |
| 2 | NVIDIA Hauptdiskussion | +0,81 % | |
| 3 | ROCK TECH LITHIUM Hauptdiskussion | ±0,00 % | |
| 4 | Nio für normale Kommunikation | ±0,00 % | |
| 5 | TESLA MOTORS Hauptdiskussion | +0,27 % | |
| 6 | CFC INDUSTRIE Hauptdiskussion | -3,70 % | |
| 7 | MICROSTRATEGY Hauptdiskussion | +1,69 % | |
| 8 | BORUSSIA DORTMUND Hauptdiskussion | ±0,00 % | |
| 9 | NEL ASA Hauptdiskussion | +1,92 % | |
| 10 | BAYER Hauptdiskussion | +0,17 % | Alle Diskussionen |